Search

Your search keyword '"Mackay, Alan"' showing total 216 results

Search Constraints

Start Over You searched for: Author "Mackay, Alan" Remove constraint Author: "Mackay, Alan" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
216 results on '"Mackay, Alan"'

Search Results

1. Diffuse pediatric high-grade glioma of methylation-based RTK2A and RTK2B subclasses present distinct radiological and histomolecular features including Gliomatosis cerebri phenotype

2. GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant

3. Inhibition of exosome biogenesis affects cell motility in heterogeneous sub-populations of paediatric-type diffuse high-grade gliomas

4. An exceptionally rare case of a diffuse midline glioma with concomitant H3.1 K27M and G34R mutations in the HIST1H3C (H3C3) gene.

5. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

6. Gliomatosis cerebri in children:A poor prognostic phenotype of diffuse gliomas with a distinct molecul profile

7. PATH-23. CLINICOPATHOLOGIC ANALYSIS OF NOVEL METHYLATION CLUSTERS OF IDH-WILDTYPE DIFFUSE GLIOMAS

8. HGG-17. SINGLE-CELL AND SPATIAL ANALYSES DECIPHER THE UNIQUE INVASIVE GROWTH PATTERN OF GLIOMATOSIS CEREBRI

9. Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

10. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

11. Abstract 234: ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput in vivo testing

12. Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

13. Supplementary Table 3 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

14. Supplementary Table 2 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

15. Data from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

16. Supplementary Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

17. Press Conference from Functional Viability Profiles of Breast Cancer

18. Data from Functional Viability Profiles of Breast Cancer

19. Supplementary Methods from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

20. Supplementary Table S3 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

21. Supplementary Figures 1-8, Tables 1-9 from Functional Viability Profiles of Breast Cancer

22. Supplementary Figures S1-S3 from Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

23. Data from Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

24. Supplementary Figure Legends from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

25. Supplementary Table 1 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

26. Supplementary Table 4 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

27. Supplementary Figures 1 - 13 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

28. Table S2 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis

29. Supplementary Figure SF2 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial

31. Supplementary Table ST5 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial

32. Supplementary Data from Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers

33. Supplementary Figure 1 from FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas

34. Supplementary Data from A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas

35. Supplementary Figures 1-2, Supplementary Tables 1-2 from Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer

36. Supplementary Table S3 from A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas

37. Figure S5 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis

38. Supplementary Table Legends from A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas

39. Supplementary Table 2 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

40. Supplementary Data from Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas

41. Supplementary Table 1 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

42. Supplementary Tables 7 - 8 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

43. Supplementary Materials from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial

44. Supplementary Figures 1 - 3 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

45. Supplementary Figure Legends, Table Legends from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

46. Supplementary Data from PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas

47. Supplementary Tables 3 - 6 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

48. Supplementary Tables 11 - 13 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

49. Supplementary Figures 1-7, Methods from FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo

50. Supplementary Tables 9 - 10 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

Catalog

Books, media, physical & digital resources